


 Cite this: *RSC Adv.*, 2025, 15, 12057

Cytotoxicity of Pd(II) and Pt(II) complexes of 2',6'-di(thiazol-2-yl)-2,4'-bipyridine: insights into the mode of cell death and cell cycle arrest†

 Ahmed M. Mansour,^{‡*ab} Krzysztof Radacki,^{‡c} Ola R. Shehab,^{‡*b} Gamal A. E. Mostafa,^d Essam A. Ali^d and Mahmoud T. Abo-Elfadl^{‡ef}

Square-planar complexes were synthesized by the reaction of 2',6'-di(thiazol-2-yl)-2,4'-bipyridine with either Na₂[PdCl₄] or K₂[PtCl₄], and these were thoroughly structurally characterized using some analytical and spectroscopic techniques. Density functional theory computations, including natural bond orbital analysis, were used to complement the experimental work to gain insight into the natural charge and electronic arrangement of the metal ion, as well as the strength of the metal–ligand bonds. The Pd(II) complex exhibited exceptional cytotoxicity against the A549 and HCT-116 cell lines with IC₅₀ values of 60.1 ± 3.45 and 23.8 ± 1.48 μM, respectively. Unfortunately, the Pd(II) complex was harmful to the Vero normal cell line with an IC₅₀ value of 24.5 ± 2.13 μM. The Pt(II) complex is unstable and has a high likelihood of exchanging the chlorido ligand for solvent molecules such as DMSO. The fluorescent-stain photos of the treated HCT-116 cells with the Pd(II) complex showed increased apoptotic bodies, indicating both early (18%) and late apoptosis (32%), as well as a necrosis ratio of about 10%. Flow cytometric analysis demonstrated that a cell arrest was induced by the Pd(II) complex on HCT-116 cells in the G₂/M phase.

Received 27th January 2025

Accepted 8th April 2025

DOI: 10.1039/d5ra00647c

rsc.li/rsc-advances

1 Introduction

The metal-based anticancer agent cisplatin is one of the most widely used clinical medications for treating a variety of tumours despite its adverse effects, which include vomiting, neurotoxicity, nephrotoxicity, and ototoxicity. Even now, some tumours become resistant to cisplatin, which lessens its effectiveness.^{1,2} Therefore, the development of more effective cancer therapy treatments is therefore necessary.³ There are two main approaches to develop new anticancer drugs based on the cisplatin structure and its next generations. One way to deal

with the side effects of cisplatin is to synthesize analogues by substituting the labile chlorido or inert ammine ligands.^{4–7} The second approach to counteract the negative side effects of cisplatin includes using metal ions other than Pt(II), such as Pd(II), Au(III), Ru(II), and Pt(IV). One strategy to improve the effectiveness of cisplatin against the resistant cell lines is co-treatment. Given the structural similarities between the d⁸ metal ions, the closely related Pd(II) complexes have garnered lots of interest in this area.^{6,8–12} Since Pd(II) complexes exchange ligands 10⁵ times more quickly than their Pt(II) analogues and are more likely to interact with sulfur-donor biomolecules and other cell components, they are indeed labile. The quick exchange and/or hydrolysis of Pd(II) complexes was resolved with the aid of certain chelating ligands that offered high thermodynamic stability and a kinetically inert nature.

One of the intriguing ligands that is widely utilized to create biologically active Pd(II) and Pt(II) complexes for addressing the high lability of Pd(II) complexes is 2,2':6',2''-terpyridine.^{13,14} Due to its exceptional complexing ability towards a variety of metal ions, 2,2':6',2''-terpyridine has been widely used as a tridentate motif among the well-known ligands used as building blocks for the synthesis of diverse complexes containing nitrogen donor ligands.^{15–17} When applied to the Cellosaurus cell line (Bel-7402), the Pd(II) complex of 4'-(4-(2-(piperidin-1-yl)ethoxy)phenyl)-2,2':6',2''-terpyridine (Fig. 1a) is seven times more cytotoxic (IC₅₀ = 1.01 ± 0.13 μM) than cisplatin (IC₅₀ = 8.12 ± 0.20 μM).¹⁸ It has shown that the Pd(II) complex of 2,2':6',2''-

^aDepartment of Chemistry, United Arab Emirates University, Al-Ain, United Arab Emirates. E-mail: Mansour_am@uaeu.ac.ae; mansour@sci.cu.edu.eg; inorganic_am@yahoo.com

^bDepartment of Chemistry, Faculty of Science, Cairo University, Gamma Street, Giza, Cairo 12613, Egypt. E-mail: Olashehab@sci.cu.edu.eg

^cInstitut für Anorganische Chemie, Julius-Maximilians-Universität Würzburg, Am Hubland, D-97074 Würzburg, Germany

^dDepartment of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia

^eCancer Biology and Genetics Laboratory, Centre of Excellence for Advanced Sciences, National Research Centre, Dokki, Giza 12622, Egypt

^fBiochemistry Department, Biotechnology Research Institute, National Research Centre, Dokki, Giza 12622, Egypt

† Electronic supplementary information (ESI) available. See DOI: <https://doi.org/10.1039/d5ra00647c>

‡ These authors contributed equally.







Fig. 1 Previously reported cytotoxic Pd(II)- and Pt(II)-terpyridine complexes and closely related structures, functionalized with tridentate ligands.

terpyridine (Fig. 1b) is more cytotoxic ($IC_{50} = 4.0 \pm 0.5 \mu M$) towards MCF7 cell line than the corresponding two Pd(II) complexes of 2,6-bis(*N*-pyrazol-2-yl)pyridine derivatives ($IC_{50} = 13.0\text{--}27.0 \mu M$).¹⁹ Yet, the three complexes demonstrated harm to the normal Vero cell line with $CC_{50} < 50 \mu M$. The microscopic images of the treated MCF7, with the three complexes, revealed indications of cell blebbing, early-stage apoptosis induction, and necrotic cell death. The Pd(II) terpyridine complexes (Fig. 1c), decorated with either $R=OH$ ²⁰ or I exhibited the highest level of effectiveness in inhibiting the growth of the Bel-7402 cell line within the series.²¹ However, the complex decorated with OH was less cytotoxic than cisplatin against MCF-7, A549, K562, HT-29, and HepG2.²⁰ Flow cytometry on the Bel-7402 cell line shows that the complex, with $R=OH$, prevents cell proliferation during the G_0/G_1 phase, causing most apoptotic cells to be late apoptotic.

Due to a combination of autophagic and apoptotic cell death pathways, the Pd(II) complexes of 2,6-bis(thiazol-2-yl)pyridine (Fig. 1d), adorned with 9-phenantryl and 1-pyrenyl, exhibited potency against the A2780 cell line, comparable to cisplatin.²² Reactive oxygen species were produced by both complexes, and they could be associated to the apoptotic pathway trigger. The IC_{50} values (22–26 μM) of Pt(II) complex of 2,6-bis(2-benzimidazolyl) pyridine (Fig. 1e) against HepG2 and HT29 demonstrated that it had significantly more cytotoxic activity than cisplatin. Using flow cytometric analysis and fluorescence microscopy, it was shown that this complex caused apoptotic cell death, as shown by morphological alterations, loss of mitochondrial *trans*-membrane potential, and a significant increase of cells in the sub G_0/G_1 phase of the cell cycle.²³ The Pd(II) complex of the mentioned ligand demonstrated selectivity and cytotoxic potency against HeLa cells ($IC_{50} = 16.3 \pm 4.9 \mu M$) that were at par with cisplatin ($IC_{50} = 11.4 \pm 3.5 \mu M$).²⁴ In contrast to cisplatin, this Pd(II) complex did not significantly trigger caspase-dependent apoptosis.

Herein, we report the synthesis and characterization of 2',6'-di(thiazol-2-yl)-2,4'-bipyridine (**1**) and its Pd(II) and Pt(II) complexes ($[MCl(\mathbf{1})] \cdot PF_6$ ($M = Pd(II)$ **2** and Pt(II) **3**) (Scheme 1) using a variety of analytical and spectroscopic tools. The



Scheme 1 Synthesis of 2',6'-di(thiazol-2-yl)-2,4'-bipyridine (**1**), and its Pd(II) (**2**) and Pt(II) (**3**) complexes.

stability of the complexes was examined before researching their antiproliferative properties against five cancerous and one normal cell lines. The Pt(II) complex is unfortunately unstable and has a high likelihood of exchanging the chlorido ligand for DMSO. Therefore, the Pt(II) complex was not further investigated for its cytotoxic properties because it showed low and poor stability in a media appropriate for biological applications. A singlet oxygen trap named 1,3-diphenyliso-benzofuran was utilized to track the production of the reactive oxygen species. The effect of **2** on the cell cycle was also investigated by the flow cytometry technique. The acridine orange/ethidium bromide stain (AO/EtBr) is used to regulate the manner of cell death that occurs when the HCT-116 cell line (for example) is treated with complex **2**.

2 Results and discussion

2.1 Synthesis and characterization

Scheme 1 illustrates how 2-pyridinecarboxaldehyde and two equivalents of 2-acetylthiazole reacted in strongly basic media (potassium *tert*-butoxide and ammonia) to produce 2',6'-di(thiazol-2-yl)-2,4'-bipyridine (**1**).^{25,26} Ligand **1** was structurally characterized by IR (Fig. S1†), ¹H NMR (Fig. S2†), ¹³C NMR (Fig. S3†), {¹H, ¹H} COSY (Fig. S4†), and {¹H, ¹³C} HSQC (Fig. S5†). In CDCl₃, the ¹H NMR spectrum (Fig. S2†) of **1** is characterized by a singlet signal at δ 8.84 ppm assigned to the protons of the central ring, as well as two doublets, and two triplets, at δ 8.77, 7.99, 7.82 and 7.35 ppm, due to the terminal pyridine ring. For thiazole ring, two doublets are observed at δ 7.96 and 7.48 ppm in the ¹H NMR spectrum of **1**. After being treated with a saturated solution of NH₄PF₆, the reaction between **1** and sodium tetrachloropalladate produced **2**. As **1**, the Pd(II) complex **2** was fully characterized by IR (Fig. S6†), NMR (Fig. S7–S12†) (¹H, ¹³C, {¹H, ¹H} COSY, {¹H, ¹³C} HSQC, ¹⁹F and ³¹P), electrospray ionization mass spectrometry (Fig. S13†) and elemental analysis. In the positive mode, the ESI MS spectrum (Fig. S13†) of **2** is characterized by a fragment at m/z 464.9059 (calcd 464.9065) due to $\{M-PF_6\}^+$ (M is a molecular formula of **2**). A review of the literature revealed that terpyridine ligands and their analogues typically coordinate to metal ions in one of three ways: either in a tridentate fashion *via* all three nitrogen donor atoms,^{27–29} in a bidentate $\kappa^2-N^{1,1'}$ mode where one of the two outer heterocyclic rings is bent out of the mean plane of the other two coordinated centers,^{30–32} or in a few instances, in a monodentate κ^1-N^1 binding mode.³³ A singlet ¹H NMR signal for the central pyridine-H3/H5 indicates that the ligand **1** is in the tridentate chelation mode. The PF₆[−]



counterion was traced by observing the septet ^{31}P NMR signal (Fig. S11†) and doublet ^{19}F NMR signal (Fig. S12†) at $\delta -144.2$ ($^1J_{\text{PF}} = 711$ Hz) and -70.1 ppm ($^1J_{\text{PF}} = 711$ Hz), respectively. After **1** and $\text{K}_2[\text{PtCl}_4]$ reacted together, NH_4PF_6 was added, yielding **3**. Unfortunately, complex **3** decomposes in DMSO (Fig. S14†) because of the quick exchange of the chlorido ligand with DMSO. Besides, complex **3** has low solubility in most of the organic solvents. This has been noted for some Pt(II) terpyridine complexes.^{28,34} Therefore, complex **3** was structurally characterized by IR (Fig. S15†), solid-state NMR [^{13}C , ^{15}N , ^{19}F , and ^{31}P] (Fig. S16–S19†), ESI MS (Fig. S20†), and elemental analysis. The ESI MS spectrum (Fig. S20†) of **3**, in the positive mode, displays a unique fragment at m/z 552.9657 (calcd 552.9679) due to $\{\text{M}-\text{PF}_6\}^+$ (M is a molecular formula). In ^{31}P (Fig. S17†) and ^{19}F (Fig. S18†) NMR spectra of **3**, the PF_6^- signals are detected at $\delta = -143.9$ and -68.3 ppm, respectively. The ^{15}N NMR spectrum (Fig. S19†) of **3** is characterized by a signal at $\delta -168.6$ ppm, which is typical for both the Pt central atom and the nitrogen *trans*-to Cl.^{34–36}

2.2. Density functional theory calculations

The tridentate coordination mode of **1** towards Pd(II) and Pt(II) ions was shown by the spectroscopic and analytical data in the previous section. The geometries around **2** and **3** could be illustrated as square-planar, defined by a tridentate *N,N,N*-ligand, and chlorido ligand. The local minimum structures of **2** and **3** (Fig. S21 and Fig. S22†), in the ground state, were attained by optimizing the models representing their molecular structures, using the Becke 3-parameter (exchange) Lee–Yang–Parr functional^{37,38} and LANL2DZ basis set^{39,40} and by validating as a minimum on the potential energy surface by computing the vibrational modes at the same computational level of theory. Tables S1 and S2† contain the atomic coordinates for the local minimum structures of **2** and **3**. Selected bond lengths and angles of the local minimum structures of **2** and **3** are given in Table 1. In both complexes, the thiazole *trans*- M–N bonds are the same, but the ones to the Pt(II) ion are 0.020 Å shorter than

the ones to the Pd(II) ion. The reason for this is that Pd(II) and Pt(II) ions differ in size. Similarly, Pt(II) is 0.016 Å closer to the central pyridine nitrogen than the Pd(II) ion. In contrast, the Pt–Cl is 0.034 Å longer than the Pd–Cl, which could be the cause of the complex's instability in DMSO due to the quick exchange between Cl and the solvent molecules. In both complexes, the corresponding *cis*- and *trans*-angles around the metal center are equal. This means that the shift of the metal center from Pd(II) to Pt(II) ion does not cause any change in the bond angles. Since the bond angles deviate from the linearity, the geometries of **2** and **3** should be regarded as distorted square planar.

The natural charge of the metal center, population of the d-orbitals, type of bonding, and strength of the M–N bonds (pyridine *vs.* triazole) in **2** and **3** could be ascertained using the natural bond orbital (NBO) analysis of Weinhold and co-workers⁴¹ and the second order perturbation theory analysis. Moreover, the NBO approach has been extensively used to assess the intra- and intermolecular contacts and offers a good basis for researching conjugative interactions or charge transfer in several molecular systems. To ascertain the contributions of atomic orbitals to σ or π natural bond orbital, for bonded atom pairs, NBO analysis was performed. In general, the types of NBOs are bonding, core (CR), and lone pair (LP). The ideal Lewis structure is composed of Lewis σ -type (donor) NBOs and non-Lewis σ -type (acceptor) NBOs. Filled NBOs define covalency in the molecules, while anti-bonds represent vacant valence-shell capacity. Weak valence anti-bond occupancies are a sign of an intricate departure from a localized Lewis picture, or actual “delocalization effects.” According to NBO analysis, the electronic configuration of the Pd(II) ion in **2** is $[\text{Kr}] 5s^{0.34}4d^{8.83}5p^{0.30}5d^{0.01}$. Thus, 35.99 core electrons, 9.46 valence electrons, and 0.01 Rydberg electrons give 45.46 electrons. Since the surrounding ligands donate an electron density to the metal center, the calculated natural charge on the Pd ion (0.534e) is significantly less than the formal charge (+2) (Table 2). The occupancies of 4d orbitals are as follows: $d_{xy}^{1.97701}d_{xz}^{1.93809}d_{yz}^{1.95669}d_{x^2-y^2}^{1.01202}d_{z^2}^{1.94578}$. The four bonds

Table 1 Selected calculated bond lengths (Å) and angles (°) of **2** and **3** obtained at B3LYP/LANL2DZ level of theory

2		3	
Pd–N(py)	1.990 Å	Pt–N(py)	1.974 Å
Pd–N(thiazole)	2.055 Å	Pt–N(thiazole)	2.035 Å
Pd–Cl	2.348 Å	Pt–Cl	2.382 Å
N(py)–Pd–N(thiazole)	79.9°	N(py)–Pt–N(thiazole)	80.1°
N(thiazole)–Pd–Cl	100.2°	N(thiazole)–Pt–Cl	99.7°
N(thiazole)–Pd–Cl	100.0°	N(thiazole)–Pt–Cl	99.9°
N(py)–Pd–Cl	179.8°	N(py)–Pt–Cl	179.9°
N(thiazole)–Pd–N(thiazole)	159.7°	N(thiazole)–Pt–N(thiazole)	160.3°

Table 2 Electronic configuration and natural charge of the metal centre, as well as population of d-subshell in **2** and **3**

Complex	Electronic arrangement of Pd atom	d_{xy}	d_{xz}	d_{yz}	$d_{x^2-y^2}$	d_{z^2}	Natural charge
2	$[\text{Kr}]5s^{0.34}4d^{8.83}5p^{0.30}5d^{0.01}$	1.97701	1.93809	1.95669	1.01202	1.94578	0.534e
3	$[\text{Xe}]6s^{0.51}5d^{8.62}6p^{0.31}6d^{0.01}$	1.96248	1.88053	1.91837	0.96476	1.88930	0.560e



that form between Pd and the N or Cl-atoms can be explained by NBO analysis as the donation of electron density from each nitrogen atom's lone pair (LP) orbital to palladium molecular orbitals. Alternatively, the electronic arrangement of Pt(II) ion in **3** is $[\text{Xe}]6s^{0.51}5d^{8.62}6p^{0.31}6d^{0.01}$. Thus, 67.98 core electrons, 9.43 valence electrons, and 0.01 Rydberg electrons give the 67.98 electrons. The computed Pt ion natural charge (0.560e) is comparable to the Pd natural charge. The occupancies of 5d orbitals are as follows: $d_{xy}^{1.96248} d_{xz}^{1.88053} d_{yz}^{1.91837} d_{x^2-y^2}^{0.96476} d_{z^2}^{1.88930}$. Similar to **2**, the four bonds in **3** might be accounted for as an electron donation to the Pt ion from the coordination sites, with the exception of the bond of the central pyridine ring, which has a slightly covalent character. This may be seen in the *trans*-effect, the elongation of the Pt-Cl bond, and thus the quick solvent-Cl exchange. For **3**, the $\sigma(\text{Pd-N})$ bond (N is the pyridine nitrogen) is formed from a $sp^{2.76}$ hybrid on N atom, which is a mixture of 26.63% s and 73.37% p, and $sp^{0.36}d^{5.81}$ hybrid orbital on Pt atom (a mixture of 14.60% s, 5.24% p, and 5.49% d). NBO analysis implied that the $\sigma(\text{Pt-N})$ bond is strongly polarized towards the N atoms with about 74.85% of electron density concentrated on the N atom.

Hyperconjugation is the stabilizing effect caused by the overlap of two orbitals, one of which is occupied and the other is electron deficient. The second-order perturbation theory and the Fock Matrix in NBO basis were used to determine the hyperconjugative interaction energy between the acceptor and donor orbitals. The strength of the electronic interactions between the donors such as the coordination sites of **1** and acceptors *e.g.*, Pd(II) ion is indicated by the second-order interaction energy (E^2) (Table 3). The E^2 values of LP(1)N(triazole) \rightarrow RY*(4)Pd are equal, 0.74 kcal⁻¹ mol⁻¹. However, these two interactions are weaker than the corresponding one from the pyridine ring, 1.96 kcal⁻¹ mol⁻¹. The interaction LP(4)Cl \rightarrow RY*(4)Pd has E^2 value of 0.27 kcal⁻¹ mol⁻¹. In the case of **3**, the LP(1)N(triazole) \rightarrow RY*(9)Pt, $\sigma(\text{Pt-N}(\text{pyridine})) \rightarrow$ RY*(9)Pt and LP(4)Cl \rightarrow RY*(9)Pt have E^2 values of 1.48, 0.56 and 1.32 kcal⁻¹ mol⁻¹. Once more, both triazole ligands have equal and greater interactions than the chlorido ligand.

2.3. Time-dependent density functional calculations

Time-dependent density functional theory (TDDFT) calculations were carried out in the singlet state using a Becke 3-parameter (exchange) Lee-Yang-Parr functional^{37,38} with LANL2DZ basis set^{39,40} and polarizable continuum solvation model (DMSO),⁴² to gain an insight into the nature of the electronic transitions expected to be observed in the electronic spectra of **2** and **3**. The computed electronic spectra (Fig. S23†) were modelled using the Gauss-Sum software. A Gaussian convolution

was utilized for each excited state, with a full width at a maximum of 3000 cm⁻¹. The calculated electronic transitions, their energies, and assignments are tabulated in Table S3.† The computed excitation state energies with transition strength ($f > 0.05$) were considered. The electronic spectrum of **2** shows two bands at 273 and 321 nm as well as a shoulder at 403 nm due to HOMO \rightarrow LUMO+3, HOMO-1 \rightarrow LUMO+1 and HOMO \rightarrow LUMO, in that order. As shown in Fig. 2, HOMO and HOMO-1 are mostly d(Pd)/p(Cl), while the orbitals of the LUMOs stated in the above transitions are obtained from $\pi(\text{ligand})$. Therefore, the three main transitions featuring the electronic spectrum of **2** are mainly MLCT in nature. On the other hand, the calculated electronic absorption spectrum of **3** is characterized by three main bands at 295, 350, and 454 nm corresponding to HOMO-6 \rightarrow LUMO+1, HOMO-5 \rightarrow LUMO and HOMO \rightarrow LUMO, respectively. Whereas LUMO is mostly made up of the ligand π -framework with a minor contribution from d(Pt), HOMO orbitals are mostly contained upon d(Pt)/p(Cl). Thus, the lowest energy transition at 454 nm is a combination of MLCT/d-d. Similarly, the transition at 350 nm is MLCT/d-d. The transition at 295 nm is mainly LLCT in nature.

2.4. Cell viability assay

The cytotoxicity of **2** was assessed against Human epithelial mammary gland breast adenocarcinoma (MCF7), human epithelial hepatocellular carcinoma (HepG2), human epithelial-like lung carcinoma (A549), human epithelial large intestine colorectal carcinoma (HCT-116), and normal epithelial kidney of an African green monkey, Vero cell line, using the MTT assay. All cell lines were obtained from the American Type Cell Culture Bank (ATCC, Manassas, USA). Because complex **3** demonstrated low stability in DMSO and poor solubility in a medium suitable for biological applications, its cytotoxic properties were not further studied. For a duration of 24 h, the normal and malignant cultures were co-incubated with **2** at concentrations ranging from 5.13 to 164 μM . The concentration (IC₅₀ value \pm SD) (Table 4) required to reduce the cell growth by 50% was determined for **2** (Fig. S24†) and cisplatin (Fig. S25†). The viability of the examined cells is not significantly impacted by the medium. The compound exhibited varying degrees of cytotoxicity against the distinct cell lines that were being studied. Complex **2** demonstrated a strong effect on A549 and HCT-116 cell lines, with IC₅₀ values of 60.1 \pm 3.45 and 23.8 \pm 1.48 μM , respectively, while remaining safe on the MCF7 and HepG2 cell lines. Unfortunately, the Pd(II) complex was harmful to the Vero normal cell line with an IC₅₀ value of 24.5 \pm 2.13 μM . As can be shown from Table 4, complex **2** exhibits cytotoxicity against HCT-111 and Vero cell lines that is comparable to that of cisplatin.

Table 3 Selected second-order interaction energy, E^2 kcal⁻¹ mol⁻¹ between donor and acceptor orbitals in **2** and **3**

Complex	M-N and M-Cl interactions		
2	LP(1)N(triazole) \rightarrow RY*(4)Pd = 0.74	LP(1)N(pyridine) \rightarrow RY*(4)Pd = 1.96	LP(4)Cl \rightarrow RY*(4)Pd = 0.27
3	LP(1)N(triazole) \rightarrow RY*(9)Pt = 1.48	$\sigma(\text{Pt-N}(\text{pyridine})) \rightarrow$ RY*(9)Pt = 0.56	LP(4)Cl \rightarrow RY*(9)Pt = 1.32






Fig. 2 Selected frontier molecular orbitals of **2** (left) and **3** (right) obtained by B3LYP/LANL2DZ method. The electronic transitions were obtained at the same level of theory.

Table 4 The IC₅₀ of **2** and cisplatin against each cell line (μM)

Complex	MCF7	HepG2	A549	HCT-116	Vero
2	—	—	60.1 ± 3.45	23.8 ± 1.48	24.5 ± 2.13
Cisplatin	110.58 ± 12.5	27.95 ± 2.5	8.71 ± 0.5	14.61 ± 1.1	17.09 ± 1.4

2.5. Mode of cell death

The acridine orange/ethidium bromide stain (AO/EtBr) is used to regulate the manner of cell death that occurs when the HCT-116 cell line (for example) is treated with **2**. The necrotic cells as well as the early and late apoptotic cells are shown when the exclusion dye, ethidium bromide, diffuses through the ruined cell membranes and attaches itself to the DNA. The different colors of orange to red, yellowish green, and yellowish orange are utilized for distinguishing between necrotic, late, and early apoptotic cell types. The photos and cell death distribution are presented in Fig. 3. By using the fluorescent dye of AO/EtBr, the HCT-116 cells treated with **2** at a sub-toxic dose (11.5 μM) for 24 h showed the largest late apoptotic alterations (32%) compared to only 3% in the control cells. The cell death mechanism also displays early apoptosis, with ratios of 18% and 12% in cells for **2** and control, respectively. The cells treated with **2** showed a necrosis ratio of roughly 10%, while the control cells showed no necrosis.

2.6. Cell cycle

One of the main factors in the development and spread of cancer is the dysregulation of cell cycle progression, which results in unchecked cell growth halt and excessive cell proliferation.⁴³ The first sign that complex **2** is interfering with the cellular process is a change in the distribution of cells across the phases of mitotic division when compared to samples that were

not treated. Though there may be many different processes causing cells to accumulate during a given stage of the cell cycle, these findings offer justification for choosing which direction to focus future research. Based on the inhibitory effect on cell proliferation, the effect of **2** on the cell cycle of HCT-116 cells was examined. The cell cycle distribution of HCT-116 cells treated with a sub-toxic dose of **2** (11.5 μM) for 24 h was examined by flow cytometric analysis of the DNA content. The distribution of cell populations in each phase of the cell cycle is shown in Fig. 4. The results demonstrated that the G₀/G₁ phase was significantly reduced in the cells treated with **2** as compared to the control cells (84.90% for the control and 62.12% for **2**, $p < 0.001$). By comparing the S phases of the control and the cells treated with **2**, there was no significant difference among the control cells (14.00%) and **2** (18.18%, $p > 0.05$). On the other hand, there was significant cell arrest in the G₂/M phase in cells treated with **2** (19.3%) compared to the control cells (1.1%) with a high significant value $p < 0.001$. These results indicated that the antiproliferative mechanism induced by **2** on HCT-116 cells was cell arrest in the G₂/M phase.

2.7. Reactive oxygen species

It is well recognized that the aerobic cells' mitochondrial oxidative metabolism results in the production of reactive oxygen species (ROS). When properly controlled, ROS can act as ubiquitous mediators of post-translational signalling and the






Fig. 3 The cell death mode of the HCT-116 cells after treatment with 2 at a sub-toxic dose of 11.5 μM for 24 h. The photos showed increased early and late apoptosis and a considerable necrosis mode. The enlarged frame photo shows the distinct variations of each cell death mode. The frequency/intensity graph is extracted from the Zen11 software to show the extent of colors intensities compared to each other, which is then converted to a bar chart graph. The data are based on a fluorescent distribution of 1000 cells. EA early apoptosis, LA late apoptosis, N necrosis. The scale bar is 20 μm , and the magnification is 20 \times .




Fig. 4 The cell cycle analysis of HCT-116 cells treated with 2 at a sub-toxic concentration of 11.5 μM , respectively, for 24 h. The distribution showed a significant decrease in the G₀-G₁ phase and a significant increase in the G₂-M phase. $**p < 0.01$, $***p < 0.001$.

control of gene expression.⁴⁴ Nonetheless, several diseases linked to aging and metabolism have one thing in common: chronically high ROS production is very detrimental to cellular constituents.⁴⁵ Interestingly, in pathological conditions, mitochondria are the main source of ROS in cells because electrons

that have accumulated in the electron transport chain as a result of disrupted metabolism can mostly escape from complex I by reverse electron flow or straight from complex III.⁴⁴ Superoxide and other strong oxidants like hydrogen peroxide and hydroxyl radical are created when these electrons are then






Fig. 5 The ROS fluorescence intensity of 2 in the HCT-116 cell compared to the positive and negative controls. The data are represented as mean \pm Sd.

carried directly to O₂. As shown in Fig. 5, the quantity of ROS generated from the treated HCT-116 was ambiguous. Although it was as high as the positive control cells (treated with the strong ROS-releasing agent; *tert*-butyl hydroperoxide) with no significant difference between them ($p = 0.32$), the ROS level was still not significantly different from the untreated negative control cells ($p = 0.11$).

3 Conclusions

In the present contribution, we reported the synthesis, and structural characterization of chlorido Pd(II) and Pt(II) complexes of the *N,N,N*-tridentate ligand, 2',6'-di(thiazol-2-yl)-2,4'-bipyridine. The experimental studies were complemented with density functional theory calculations. The Pt(II) complex disintegrated in DMSO and displayed poor solubility in the rest of the organic solvents. It is highly likely that the chlorido ligand of the Pt(II) complex was exchanged for DMSO. Therefore, Pt(II) was not investigated for its cytotoxic properties. This has been seen for some Pt(II) complexes that are structurally related.²⁸ It is evident from the local minimum structures of the Pd(II) and Pt(II) complexes that the Pt–Cl is 0.034 Å longer than the Pd–Cl. This could be the reason for the complex's instability in DMSO because of the rapid exchange between Cl and the solvent molecules. This has been confirmed by natural bond orbital analysis. On the other hand, the corresponding Pd(II) complex showed greater stability in DMSO and as a result, the complex was tested for possible cytotoxicity against normal cell types and cancer. The cell viability assay showed that the Pd(II) complex was potent to A549 and HCT-116 cell lines, with IC₅₀ values of 60.1 \pm 3.45 and 23.8 \pm 1.48 μ M, respectively, while remaining non-cytotoxic to MCF7 and HepG2 cell lines. In fact, complex 2 demonstrated greater or comparable cytotoxicity against HCT-116 in comparison to cisplatin and certain Pd(II) complexes that have been previously described; nevertheless, the other complexes might be less detrimental to normal cell lines.^{46–48} Unfortunately, the Pd(II) complex was harmful to the Vero normal cell line with an IC₅₀ value of 24.5 \pm 2.13 μ M. Treating cells with the Pd(II) complex released ROS not high enough to be significantly different from the untreated control cells. In the mode of cell death study, the fluorescent images of the treated HCT-116 cells with the Pd(II) complex, displayed


more apoptotic bodies, indicating both early (18%) and late (32%), as well as a necrosis ratio of roughly 10%. Flow cytometric analysis revealed that the antiproliferative mechanism induced by the Pd(II) complex on HCT-116 cells was a cell arrest in the G₂/M phase.

4 Experimental

4.1. Materials and instruments

Organic solvents, potassium tetrachloroplatinate, and sodium tetrachloropalladate were bought and utilized exactly as supplied. 2',6'-di(thiazol-2-yl)-2,4'-bipyridine^{25,26} was prepared by following the previously published methods. ¹H, ¹³C, ¹⁹F and ³¹P NMR spectra were recorded with Bruker-Avance 500 (¹H, 500.13 MHz; ¹³C{¹H}, 125.77 MHz; ¹⁹F, 470.59 MHz; ³¹P, 202.46 MHz) and Bruker-Avance 400 (¹H, 400.40 MHz; ¹³C{¹H}, 100.68 MHz; ³¹P, 162.08 MHz) spectrometers. Assignments of NMR signals were performed with the aid of two-dimensional NMR methods, {¹H, ¹H} COSY and {¹H, ¹³C} HSQC. A ThermoFisher Exactive Plus device equipped with an Orbitrap mass analyser was used to record electrospray mass spectra at a solvent flow rate of 50 μ l min⁻¹ and a resolution of $R = 70,000$. Elemental micro-analysis was achieved with a Vario Micro Cube analyser of Elementar Analysensysteme or an EA 3000 elemental analyzer from HEKtech. A Nicolet 380 FT-IR spectrometer equipped with a smart iFTR adapter was used to gather vibrational spectra in the solid state. The Specord 210 Plus spectrophotometer was used to record electronic absorption spectra.

4.2. Synthesis



1: (ref. 25 and 26) To a flat-bottom flask charged with 2-acetylthiazole (1 g; 7 mmol), ammonia solution (20 mL), potassium *tert*-butoxide, and ethanol (20 mL), was added 2-pyridine carboxaldehyde (0.42 g; 0.35 mmol). Directly, a dark brown colour developed. For 24 h, the reaction mixture was agitated at room temperature. As time passes, the dark-grown colour fades, and a white precipitate forms. Filtration was used to collect the precipitate, which was then repeatedly cleaned with water and diethyl ether. IR (ATR): $\nu = 3055, 1586, 1503, 1430, 1251, 1067, 991, 783$ cm⁻¹. ¹H NMR (CDCl₃, 500.13 MHz): $\delta = 8.84$ (s, 2H, py-H3'/H5'), 8.77 (d, ³J_{H,H} = 4.8 Hz, 1H, py-H6), 7.99 (d, ³J_{H,H} = 7.9 Hz, 1H, py-H3), 7.96 (d, ³J_{H,H} = 3.22 Hz, 2H, thiazole-H4), 7.82 (td, ³J_{H,H} = 7.89 Hz, ⁴J_{H,H} = 1.81 Hz, 1H, py-H4), 7.48 (d, ³J_{H,H} = 3.15 Hz, 2H, thiazole-H5), 7.35 (m, 1H, py-H5) ppm. ¹³C NMR (CDCl₃, 125.77 MHz): $\delta = 168.8, 153.9, 151.9, 150.2, 149.1, 144.3, 137.2, 124.0, 122.0, 121.2, 117.8$ ppm. C₁₆H₁₀N₄S₂: C



59.61, H 3.13, N 17.38, S 19.89; found C 59.75, H 3.12, N 17.54, S 19.60.

2: Methanol (25 mL) was added to a round-bottom flask that was charged with **1** (0.5 mmol; 161 mg) and Na₂PdCl₄ (0.55 mmol; 147 mg), and then the reaction mixture was heated to reflux for 12 h. Yellow precipitate was collected by filtration, washed with methanol (3 × 5 mL), and chloroform (3 × 5 mL). The complex was treated with NH₄PF₆ (1.0 mmol; 163 mg) in 75% (acetone/water) mixture. Stirring was done overnight. Yellow precipitate was collected by filtration, washed with water (5 × 5 mL), diethyl ether, and dried in *vacuo*. IR (ATR): $\nu = 3065$ (br, CH), 1611, 1472, 1330, 1252, 840 and 779 cm⁻¹. ¹H NMR (DMSO-d₆, 500.13 MHz): $\delta = 9.14$ (s, 2H, py-H3'/H5'), 8.90 (m, 1H, py-H6), 8.51 (m, 1H, py-H3), 8.40 (m, 2H, thiazole-H4), 8.18 (m, 1H, py-H4), 7.96 (m, 2H, thiazole-H5), 7.71 (m, 1H, py-H5) ppm. ¹³C-NMR (DMSO-d₆, 125.77 MHz): $\delta = 167.8, 152.5, 150.4, 150.3, 141.5, 138.1, 128.3, 126.4, 125.1, 123.5, 123.0$ and 120.6 ppm. ³¹P NMR (DMSO-d₆, 202.46 MHz): $\delta = -144.2$ (sept, ¹J_{PF} = 711 Hz, PF₆⁻). ¹⁹F NMR (DMSO-d₆, 470.59 MHz): $\delta = -70.1$ (doublet, ¹J_{PF} = 711 Hz, PF₆⁻) ppm. ESI-MS (positive mode, DMSO/methanol): $m/z = 464.9058$ {M-PF₆⁻}⁺ (M: molecular formula). C₁₆H₁₀ClF₆N₄PPdS₂·H₂O: C 30.64, H 1.93, N 8.93, S 10.22; found C 30.77, H 1.59, N 9.25, S 10.11.

3: To a flat-bottom flask charged with **1** (0.5 mmol; 161 mg) and methanol (30 mL), was added 5 mL aqueous solution of K₂PtCl₄ (0.5 mmol; 205 mg). The reaction mixture was heated to reflux for 12 h, whereupon brown precipitate formed. The complex was collected by filtration, washed with chloroform (3 × 5 mL), and water (3 × 5 mL). Next, the complex was suspended in 75% (acetone/water) solution that included NH₄PF₆ (1.0 mmol; 163 mg). Stirring was done overnight. Brown precipitate was collected by filtration, washed with water, diethyl ether, and dried in *vacuo*. IR (ATR): $\nu = 3065, 1611, 1457, 1252, 1208, 840, 779$ cm⁻¹. The complex decomposed in DMSO-d₆ (see Fig. S15[†]) and had poor solubility in DMF-d₇. Solid-state NMR analyses were done. ¹³C NMR (solid-state, 100.68 MHz): $\delta = 168.9, 166.9, 165.8, 160.4, 159.3, 149.9, 141.3, 138.1, 127.4, 126.3, 122.1, 120.0$ and 116.7 ppm. ³¹P NMR (solid-state, 161.94 MHz): $\delta = -143.9$ ppm (sept, ¹J_{PF} = 710 Hz, PF₆⁻). ¹⁹F NMR (solid-state, 396.5 MHz): $\delta = -68.3$ (br, PF₆⁻) ppm. ESI-MS (positive mode, DMSO/methanol): $m/z = 552.9658$ {M-PF₆⁻}⁺ (M: molecular formula). ¹⁵N NMR (solid-state, 40.56 MHz): $\delta = -168.6$ ppm. C₁₆H₁₀ClF₆N₄PPtS₂·3H₂O: C 25.56, H 2.14, N 7.45, S 8.53; found C 25.41, H 2.09, N 7.39, S 8.46.

4.3. Density functional theory calculations

Ground-state geometry optimizations of **2** and **3**, were executed using Gaussian03,⁴⁹ with a Becke 3-parameter (exchange) Lee–Yang–Parr functional^{37,38} and LANL2DZ basis set.^{39,40} The local minimum structure of the complex was verified to be the lowest on the potential energy surface by computing their vibrational modes. No imaginary vibrations were detected. Using the computed approach utilized in the optimization procedure, natural bond orbital (NBO) analysis of Weinhold and co-workers was carried.⁴¹ Time-dependent density functional

theory (TDDFT) calculations were done also by B3LYP/LANL2DZ method, including the polarizable continuum model (PCM).⁴² Visualization of the electronic spectra and frontier molecular orbitals was achieved using Gaussview03.⁵⁰

4.4. Cell viability assay

4.4.1. Cell lines and cell culture. Human epithelial mammary gland breast adenocarcinoma (MCF7), human epithelial hepatocellular carcinoma (HepG2), human epithelial-like lung carcinoma (A549), human epithelial large intestine colorectal carcinoma (HCT116), and normal epithelial kidney of an African green monkey, Vero cell line, were all obtained from the American Type Cell Culture (ATCC, USA). They were all routinely grown in Dulbecco's Modified Eagle (DMEM) medium, which has a high glucose content. 10% fetal bovine serum, 1% antibiotic-antimycotic cocktail, and 2 mM L-glutamine comprise the total medium. All from Nuaille, France's Biowest. Cells were maintained at 37 °C and sub-confluency in humidified air containing 5% CO₂. Following the trypsin/EDTA treatment at 37 °C, the monolayer cells were gathered for sub-culturing. Cells were utilized after confluence reached 75%.

4.4.2. Cell viability assay. The original published protocol⁵¹ served as the basis for the MTT colorimetric assay (MTT = 3-[4,5-dimethylthiazole-2-yl]-2,5-diphenyltetrazolium bromide). To sum up, 1 × 10⁴ cells per well were seeded in a serum-free medium into a flat bottom 96-well microplate, treated with 20 μl of different concentrations of the tested compounds and finally the plates were then incubated for 24 h at 37 °C, in a humidified 5% CO₂ atmosphere. Complex **2** was used at final concentrations ranging from 164 to 5.13 μM. Following incubation, media were taken out, 40 μl of the MTT solution per well was added, and the mixture was incubated for a further 4 h. To dissolve the MTT crystals, 180 μl of acidified isopropanol was added per well. After shaking the plates at room temperature, the optical density absorbance at 570 nm was measured photometrically using a microplate ELISA reader (FLUOstar OPTIMA, BMG LABTECH GmbH, Ortenberg, Germany). For every concentration, two repeats were executed, and the average was concluded. Prior to MTT assay, the stability of the aqueous DMSO solution of **2** was investigated by recording the electronic spectra over 22 h. Under these experimental conditions, the collected UV/Vis spectra (Fig. S26[†]) obtained as a function of time are nearly superimposable, suggesting a good stability of **2**.

4.4.3. Cell cycle analysis. Once the IC₅₀ of **2** was determined, 1 × 10⁶ HCT-116 cells were treated with a sub-toxic dose of **2** corresponding 11.5 μM for 24 h in 6-well cell culture plates. Afterward, the cells were trypsinized, washed with phosphate buffer saline (PBS), pelleted, and fixed with 70% ethanol. The BD Cycletest™ Plus DNA Reagent Kit (Cat. No. 340242, BD, New Jersey, USA) was used to analyze the fixed cells for cell cycle distribution. It uses propidium iodide (PI) as a DNA fluorophore. The Cytotflex flow cytometer and the CytExpert software (Beckman Coulter, Inc, California, USA) were used for carrying out the assay and analyzing the data.

4.4.4. Cell death mode detection. The HCT-116 cells were planted in 8-well cell culture slides (SPL, Seoul, South Korea) for



24 hours (2×10^4 cells/250 μL /well). After settling, 100 μM of **2** was added as the final concentration. For 24 h. After a 24 hours incubation period, the cells were washed with phosphate buffer saline (PBS) and stained using a dual Merck stain that was diluted 1:1 in PBS:ethidium bromide (100 $\mu\text{g mL}^{-1}$) and acridine orange (100 $\mu\text{g mL}^{-1}$). Ten minutes later, the slides were washed with PBS and viewed on an AxioImager Z2 fluorescent microscope using Zen 11 software (Zeiss, Jena, Germany).

4.4.5. Reactive oxygen species (ROS) determination. 100 μM of **2** was added to HCT-116 cells (1×10^5 cells per well) in a black 96-well cell culture plate, and the cells were incubated for 24 h. A fluorescent probe, 2,7-dichlorofluorescein diacetate, is used to quantify the ROS that are produced inside the cells. The ROS was measured fluorometrically at 502/520 nm excitation/emission using the Elabscience, Texas, USA kit E-BC-K138-F, by the manufacturer's procedure in comparison to ROS-releasing agent, *tert*-butyl hydroperoxide (*t*BHP) and the untreated control cells.

4.4.6. Statistics. Data is presented as mean \pm SD. Ordinary one-way ANOVA and 2-way ANOVA with multiple comparisons followed by Tukey test at 95% confidence interval were applied to compare the different concentrations and the different lightening conditions using GraphPad Prism 10.3.0 (461), for MacOS, GraphPad Software (San Diego, California USA, <https://www.graphpad.com>).

Data availability

Data is available in main text and ESI.†

Author contributions

A. Mansour: conceptualization, investigation, validation, resources, formal analysis, software, writing – original draft, writing – review & editing. K. Radacki: methodology, investigation, resources. O. Shehab: investigation, writing – review & editing. G. Mostafa, writing – review & editing, resources. E. Ali, writing – review & editing, resources. M. Abo-Elfadl: conceptualization, methodology, investigation, validation, resources, formal analysis, writing – original draft, writing – review & editing.

Conflicts of interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements

The authors extend their appreciation to the researchers Supporting Project Number (RSPD2025R1000) at King Saud University Riyadh Saudi Arabia, for funding this work. The authors wish to thank United Arab Emirates University, Al Ain, UAE, for research support. A. Mansour thanks Dr Rüdiger

Bertermann, Julius-Maximilians-Universität Würzburg, for solid-state NMR analysis.

Notes and references

- 1 A. Rennie, W. Voigt, T. Mueller, A. Fruehauf, H.-J. Schmoll, C. Beyer and W. Dempke, *Anticancer Res.*, 2005, **25**, 1147–1155.
- 2 H. Timmer-Bosscha, N. Mulder and E. De Vries, *Br. J. Cancer*, 1992, **66**, 227–238.
- 3 M. Tanaka, H. Kataoka, S. Yano, H. Ohi, K. Kawamoto, T. Shibahara, T. Mizoshita, Y. Mori, S. Tanida and T. Kamiya, *BMC Cancer*, 2013, **13**, 1–9.
- 4 A. M. Mansour and O. R. Shehab, *Dalton Trans.*, 2018, **47**, 3459–3468.
- 5 N. T. Abdel-Ghani and A. M. Mansour, *Eur. J. Med. Chem.*, 2012, **47**, 399–411.
- 6 A. M. Mansour and N. T. Abdel-Ghani, *Inorg. Chim. Acta*, 2015, **438**, 76–84.
- 7 A. M. Mansour, *Inorg. Chim. Acta*, 2016, **453**, 697–703.
- 8 T. Lazarević, A. Rilak and Ž. D. Bugarčić, *Eur. J. Med. Chem.*, 2017, **142**, 8–31.
- 9 E. Gao, C. Liu, M. Zhu, H. Lin, Q. Wu and L. Liu, *Anti-Cancer Agents Med. Chem.*, 2009, **9**, 356–368.
- 10 A. G. Quiroga and C. N. Ranninger, *Coord. Chem. Rev.*, 2004, **248**, 119–133.
- 11 A. M. Mansour, R. M. Khaled, K. Radacki, M. A. Abo-Zeid, O. R. Shehab, G. A. Mostafa, E. A. Ali and M. T. Abo-Elfadl, *Dalton Trans.*, 2024, **53**, 5073–5083.
- 12 A. M. Mansour, R. M. Khaled, K. Radacki, O. R. Shehab, G. A. Mostafa, E. A. Ali and M. T. Abo-Elfadl, *Chem. Biodiversity*, 2024, **21**, e202400363.
- 13 R. R. Panicker and A. Sivaramakrishna, *Coord. Chem. Rev.*, 2022, **459**, 214426.
- 14 R. Abhijnakrishna, K. Magesh, A. Ayushi and S. Velmathi, *Coord. Chem. Rev.*, 2023, **496**, 215380.
- 15 B. Z. Momeni, N. Davarzani, J. Janczak, N. Ma and A. S. Abd-El-Aziz, *Coord. Chem. Rev.*, 2024, **506**, 215619.
- 16 R. R. Panicker and A. Sivaramakrishna, *Coord. Chem. Rev.*, 2022, **459**, 214426.
- 17 C. Wei, Y. He, X. Shi and Z. Song, *Coord. Chem. Rev.*, 2019, **385**, 1–19.
- 18 W. Chu, Y. Wang, S. Liu, X. Yang, S. Wang, S. Li, G. Zhou, X. Qin, C. Zhou and J. Zhang, *Bioorg. Med. Chem. Lett.*, 2013, **23**, 5187–5191.
- 19 D. O. Onunga, R. Bellam, G. K. Mutua, M. Sitati, M. D. BalaKumaran, D. Jaganyi and A. Mambanda, *J. Inorg. Biochem.*, 2020, **213**, 111261.
- 20 F. Darabi, H. Hadadzadeh, J. Simpson and A. Shahpiri, *New J. Chem.*, 2016, **40**, 9081–9097.
- 21 Z. Wang, J. Li, R. Liu, X. Jia, H. Liu, T. Xie, H. Chen, L. Pan and Z. Ma, *J. Inorg. Biochem.*, 2023, **244**, 112219.
- 22 K. Choroba, B. Machura, L. R. Raposo, J. G. Małecki, S. Kula, M. Pająk, K. Erfurt, A. M. Maroń and A. R. Fernandes, *Dalton Trans.*, 2019, **48**, 13081–13093.
- 23 S. Rubino, P. Portanova, F. Giammalva, M. Girasolo, S. Orecchio, G. Calvaruso and G. Stocco, *Inorg. Chim. Acta*, 2011, **370**, 207–214.



- 24 R. O. Omondi, R. Bellam, S. O. Ojwach, D. Jaganyi and A. A. Fatokun, *J. Inorg. Biochem.*, 2020, **210**, 111156.
- 25 T. Klemens, K. Czerwińska, A. Szlapa-Kula, S. Kula, A. Świtlicka, S. Kotowicz, M. Siwy, K. Bednarczyk, S. Krompiec and K. Smolarek, *Dalton Trans.*, 2017, **46**, 9605–9620.
- 26 A. Maroń, S. Kula, A. Szlapa-Kula, A. Świtlicka, B. Machura, S. Krompiec, J. G. Małecki, R. Kruszyński, A. Chrobok and E. Schab-Balcerzak, *Eur. J. Org. Chem.*, 2017, **2017**, 2730–2745.
- 27 A. M. Mansour, *J. Mol. Struct.*, 2021, **1242**, 130737.
- 28 A. M. Mansour, *RSC Adv.*, 2021, **11**, 39748–39757.
- 29 A. M. Mansour, K. Radacki, G. A. Mostafa, E. A. Ali and O. R. Shehab, *Bioorg. Chem.*, 2024, **146**, 107262.
- 30 A. M. Mansour and K. Radacki, *Inorg. Chim. Acta*, 2020, **511**, 119806.
- 31 O. S. Taniya, D. S. Kopchuk, A. F. Khasanov, I. S. Kovalev, S. Santra, G. V. Zyryanov, A. Majee, V. N. Charushin and O. N. Chupakhin, *Coord. Chem. Rev.*, 2021, **442**, 213980.
- 32 A. M. Mansour, K. Radacki and O. R. Shehab, *Dalton Trans.*, 2021, **50**, 1197–1201.
- 33 A. Hildebrandt, N. Wetzold, P. Ecorchard, B. Walfort, T. Ruffer and H. Lang, *Eur. J. Inorg. Chem.*, 2010, **2010**, 3615–3627.
- 34 A. M. Mansour, K. Radacki, G. A. Mostafa, E. A. Ali and O. R. Shehab, *RSC Adv.*, 2023, **13**, 34826–34835.
- 35 L. Pazderski, in *Annual Reports on NMR Spectroscopy*, Elsevier, 2013, vol. 80, pp. 33–179.
- 36 W. P. Ozimiński, P. Garnuszek, E. Bednarek and J. C. Dobrowolski, *Inorg. Chim. Acta*, 2007, **360**, 1902–1914.
- 37 A. Becke, *Chem. Phys.*, 1993, **98**, 5648.
- 38 A. D. Becke, *Phys. Rev. A*, 1988, **38**, 3098.
- 39 P. J. Hay and W. R. Wadt, *J. Chem. Phys.*, 1985, **82**, 299–310.
- 40 P. J. Hay and W. R. Wadt, *J. Chem. Phys.*, 1985, **82**, 270–283.
- 41 A. E. Reed, L. A. Curtiss and F. Weinhold, *Chem. Rev.*, 1988, **88**, 899–926.
- 42 M. Cossi, V. Barone, R. Cammi and J. Tomasi, *Chem. Phys. Lett.*, 1996, **255**, 327–335.
- 43 R. Farghadani, J. Rajarajeswaran, N. B. M. Hashim, M. A. Abdulla and S. Muniandy, *RSC Adv.*, 2017, **7**, 24387–24398.
- 44 D. C. Wallace, W. Fan and V. Procaccio, *Annu. Rev. Pathol.: Mech. Dis.*, 2010, **5**, 297–348.
- 45 S. Raha and B. H. Robinson, *Trends Biochem. Sci.*, 2000, **25**, 502–508.
- 46 M. Ž. Mijajlović, M. V. Nikolić, V. V. Jevtić, Z. R. Ratković, B. S. Marković, V. Volarević, N. N. Arsenijević, S. B. Novaković, G. A. Bogdanović and S. R. Trifunović, *Polyhedron*, 2015, **90**, 34–40.
- 47 A. Savić, T. Marzo, F. Scaletti, L. Massai, G. Bartoli, R. Hoogenboom, L. Messori, R. Van Deun and K. Van Hecke, *BioMetals*, 2019, **32**, 33–47.
- 48 M. N. Alam and F. Huq, *Coord. Chem. Rev.*, 2016, **316**, 36–67.
- 49 M. J. Frisch, G. W. Trucks, H. B. Schlegel, G. E. Scuseria, M. A. Robb, J. R. Cheeseman, V. G. Zakrzewski, J. A. Montgomery, J. C. Burant, R. E. Stratmann, S. Dapprich, J. M. Millam, A. D. Daniels, K. N. Kudin, M. C. Strain, O. Farkas, J. Tomasi, V. Barone, M. Cossi, R. Cammi, B. Mennucci, C. Pomelli, C. Adamo, S. Clifford, J. Ochterski, G. A. Petersson, P. Y. Ayala, Q. Cui, K. Morokuma, D. K. Malick, A. D. Rabuck, K. Raghavachari, J. B. Foresman, J. Cioslowski, J. V. Ortiz, A. G. Baboul, B. B. Stefanov, A. L. G. Liu, I. K. P. Piskorz, R. Gomperts, R. L. Martin, D. J. Fox, T. Keith, M. A. Al-Laham, C. Y. Peng, A. Nanayakkara, C. Gonzalez, M. Challacombe, P. M. W. Gill, B. G. Johnson, W. Chen, M. W. Wong, J. L. Andres, M. Head-Gordon, E. S. Replogle and J. A. Pople, *Gaussian 03 (Revision A.9)*, Gaussian, Inc., Pittsburgh, 2003.
- 50 A. Frisch, A. B. Nielson and A. J. Holder, Gaussian, Inc., Pittsburgh, PA, 2000.
- 51 M. B. Hansen, S. E. Nielsen and K. Berg, *J. Immunol. Methods*, 1989, **119**, 203–210.

